Trials / Completed
CompletedNCT04187339
Study of NGM395 in Adult Participants
A Phase 1, Randomized, Placebo-controlled, Double-blind, Two-part Study to Evaluate the Safety and Tolerability of NGM395 in Adult Obese Patients (Part 1) and in Adult Patients With Nonalcoholic Fatty Liver Disease (NAFLD) (Part 2).
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 38 (actual)
- Sponsor
- NGM Biopharmaceuticals, Inc · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Study of NGM395 in adult participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | NGM395 | NGM395 Dose 1 |
| BIOLOGICAL | NGM395 | NGM395 Dose 2 |
| BIOLOGICAL | NGM395 | NGM395 Dose 3 |
| BIOLOGICAL | NGM395 | NGM395 Dose 4 |
| BIOLOGICAL | NGM395 | NGM395 Dose 5 |
| BIOLOGICAL | NGM395 | NGM395 Dose 6 |
| OTHER | Placebo | Placebo |
Timeline
- Start date
- 2020-02-13
- Primary completion
- 2020-10-20
- Completion
- 2021-04-22
- First posted
- 2019-12-05
- Last updated
- 2021-07-21
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT04187339. Inclusion in this directory is not an endorsement.